Find News

Filter articles

Applied Filters

Showing 81 to 90 of 649 results

Eli Lilly collaborates with AC Immune to develop Alzheimer’s treatment


Global pharmaceutical company Eli Lilly has entered into a licence and collaboration agreement with Swiss biotechnology company AC Immune.

AstraZeneca to launch CRISPR-based cancer research centre


Pharmaceutical company AstraZeneca and charity Cancer Research UK have announced that they will launch a centre to accelerate the discovery of new cancer treatments.

Appeal filed against EPO sofosbuvir patent decision

EPO, EU10-12-2018

Six organisations have appealed against the European Patent Office’s decision to uphold a patent for a key hepatitis C drug.

European pharma body criticises SPC waiver vote


The European Federation of Pharmaceutical Industries and Associations has sharply criticised an opinion on supplementary protection certificate proposals that was issued by a European Parliament committee.

UK life sciences partnership to use AI in disease detection


The UK government and the life sciences industry have partnered to develop new technology using artificial intelligence to detect diseases at an early stage.

Boehringer in research collaboration with Domain Therapeutics

Canada, France, Germany04-12-2018

German pharmaceutical company Boehringer Ingelheim has signed a research collaboration and licence agreement with French and Canadian biopharmaceutical business Domain Therapeutics.

GSK seeks to boost oncology repertoire with $5.1bn acquisition

EU, UK, US03-12-2018

GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.

AbbVie and Pfizer in Humira licensing deal


AbbVie has granted Pfizer a non-exclusive global licence to its Humira IP, as announced on Friday, November 30.

EFPIA concerned over SPC waiver amendments


Proposed amendments to the EU’s supplementary protection certificate manufacturing waiver risk “further disincentivising investment” in Europe, according to the European Federation of Pharmaceutical Industries and Associations.

NHS to save £300m in biosimilar adalimumab deals


The National Health Service England is set to make record-breaking savings after negotiating deals with five manufacturers of low-cost biosimilar versions of the NHS's most expensive drug.

Showing 81 to 90 of 649 results